Sierra Sees Momelotinib ‘Sweet Spot’ In Anemic Myelofibrosis Population

 
• By Alaric DeArment

Sierra announced Phase III results for the JAK inhibitor in anemic myelofibrosis patients with previous JAK exposure, a difficult-to-treat population. Trial investigator Ruben Mesa talked to Scrip about some of the advantages.

3-D Rendering Red Blood Cells
Sierra announced data from the Phase III MOMENTUM study of momelotinib in myelofibrosis • Source: Shutterstock

More from Strategy

More from Business